Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM15YL0)

• Drug Name: ML204 Drug Info
• Synonyms: 5465-86-1; ML204; ML 204; 4-methyl-2-(piperidin-1-yl)quinoline; 4-Methyl-2-(1-piperidinyl)-quinoline; 4-methyl-2-piperidin-1-ylquinoline; 4-Methyl-2-(1-piperidinyl)quinoline; VU0024172-3; NSC25850; AC1Q4W9R; Cambridge id 5563912; AC1L5K4A; MLS001007138; 4-methyl-2-piperidylquinoline; 4-methyl-2-piperidinoquinoline; 2-Piperidino-4-methylquinoline; GTPL4255; cid_230710; 4-methyl-2-piperidino-quinoline; SCHEMBL14975993; CHEMBL1459962; CTK5A2131; BDBM77617; DTXSID30282438; EX-A938; AOB1526; MolPort-000-220-757; HMS2704E20; BCP28617

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 230710
  CAS Number: CAS 5465-86-1
  TTD Drug ID: DM15YL0

Molecule-Related Drug Atlas

Drug(s) Targeting Short transient receptor potential channel 5 (TRPC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 1358894	DM740BS	Depression	6A70-6A7Z	Phase 2	[3]
GFB-887	DM2IJWG	Diabetic nephropathy	GB61.Z	Phase 2	[4]
2-APB	DM9AKVR	Discovery agent	N.A.	Investigative	[5]
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[6]
lysophosphatidylcholine	DMOGFVH	Discovery agent	N.A.	Investigative	[6]
KB-R7943	DMMD5W3	Discovery agent	N.A.	Investigative	[7]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[6]
bromoenol lactone	DMKQ0CA	Discovery agent	N.A.	Investigative	[8]
(-)-englerin A	DMPQBWY	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Short transient receptor potential channel 4 (TRPC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 1358894	DM740BS	Depression	6A70-6A7Z	Phase 2	[3]
2-APB	DM9AKVR	Discovery agent	N.A.	Investigative	[10]
(-)-englerin A	DMPQBWY	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Short transient receptor potential channel 4 (TRPC4)	TTX0H5W	TRPC4_HUMAN	Blocker (channel blocker)	[2]
Short transient receptor potential channel 5 (TRPC5)	TT32NQ1	TRPC5_HUMAN	Blocker (channel blocker)	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4255).
• [2] Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46.
• [3] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [4] Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int Rep. 2021 Jul 23;6(10):2575-2584.
• [5] Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490).
• [7] The Na+/Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC channels. Biochem Biophys Res Commun. 2007 Sep 14;361(1):230-6.
• [8] Bromoenol lactone inhibits voltage-gated Ca2+ and transient receptor potential canonical channels. J Pharmacol Exp Ther. 2011 Nov;339(2):329-40.
• [9] (-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 489).